DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 8,163,518
|Title:||Microwave assisted deglycosylation of proteins for molecular weight determination by mass spectrometry|
|Abstract:||Methods are presented for microwave assisted, enzymatic deglycosylation of proteins. The rate at which deglycosylation is achieved and without protein degradation facilitates rapid and accurate molecular weight determination by mass spectrometry.|
|Inventor(s):||Arnott; David P. (San Mateo, CA), Lill; Jennie (Pacifica, CA), Sandoval; Wendy N. (San Francisco, CA), Vandlen; Richard L. (Hillsborough, CA)|
|Assignee:||Genetech, Inc. (South San Francisco, CA)|
|Patent Claims:||1. A method of deglycosylation of proteins comprising treating an N-linked glycosylated protein with PNGase F enzyme under microwave radiation from 1 to 20 watts power for
an hour or less, whereby a deglycosylated protein is formed.
2. The method of claim 1 further comprising the step of applying the deglycosylated protein to a desalting media.
3. The method of claim 2 wherein the deglycosylated protein is eluted from the desalting media in a solution comprising water and an organic solvent.
4. The method of claim 1 further comprising the step of analyzing the deglycosylated protein by mass spectrometry.
5. The method of claim 4 wherein the deglycosylated protein is ionized by electrospray ionization into a mass spectrometer.
6. The method of claim 4 wherein the deglycosylated protein is ionized by MALDI.
7. The method of claim 1 wherein PNGase F is a catalytic amount relative to glycosylated protein.
8. The method of claim 7 wherein the molar ratio of PNGase F to glycosylated protein is between 1:10 to 1:1000.
9. The method of claim 1 wherein the glycosylated protein is a phospho-protein.
10. The method of claim 1 wherein the glycosylated protein is an antibody.
11. The method of claim 10 wherein the antibody is an IgG.
12. The method of claim 11 wherein the antibody is trastuzumab or bevacizumab.
13. The method of claim 11 wherein the IgG is conjugated to a detection label.
14. The method of claim 10 wherein the antibody is conjugated to a metal complexing linker.
15. The method of claim 14 wherein the metal complexing linker is selected from DOTA.
16. The method of claim 10 wherein the antibody is conjugated to a drug moiety.
17. The method of claim 1 further comprising the step of analyzing a sugar moiety removed from the glycosylated protein wherein the sugar moiety is analyzed by mass spectrometry.
18. The method of claim 17 further comprising the step of isolating the sugar moiety by high pH anion-exchange chromatography.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genentech||HERCEPTIN||trastuzumab||VIAL; INTRAVENOUS||103792||001||1998-09-25||See Pricing||Genetech, Inc. (South San Francisco, CA)||2036-04-30||RX||Orphan||search|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||001||2004-02-26||See Pricing||Genetech, Inc. (South San Francisco, CA)||2036-04-30||RX||search|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||002||2004-02-26||See Pricing||Genetech, Inc. (South San Francisco, CA)||2036-04-30||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|World Intellectual Property Organization (WIPO)||2007130875||Jan 17, 2008|
|World Intellectual Property Organization (WIPO)||2007130875||Nov 15, 2007|
|United States of America||2007259398||Nov 08, 2007|
|Japan||2009535646||Oct 01, 2009|
|Japan||5219998||Jun 26, 2013|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.